VerImmune
PrivateLast Round
VC Round
Nov 24, 2025
Total Funding Raised
$6.6M
Company Overview
VerImmune is a biotechnology company developing a first-in-class cancer immunotherapy known as Anti-tumor Immune Redirection (AIR) that utilizes a proprietary virus-inspired particle technology to redirect pre-existing immune memory to fight cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VerImmune Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
VerImmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 24, 2025 | ||||
| Grant | Apr 29, 2025 | ||||
| VC Round | Sep 23, 2024 | ||||
| Seed | Sep 20, 2023 | ||||
| Grant | Apr 29, 2023 | ||||
Seed | Jul 27, 2022 |
Key People
Founding team and executive leadership
VerImmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gaingels | Seed, VC Round |
| Mana Ventures | Seed, VC Round |
| TEDCO | VC Round |
| Ulu Ventures | Seed |
| SeedFolio | Seed |
| Proxima Ventures | VC Round |
| Beiley Biofund | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 16, 2025
Sender Aspelund appointed as Head of CMC.
VerImmune Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about VerImmune's valuation, stock price, and market status.